All In Biotech

Drug Trial Radar · NCT06390774

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

Last checked: Nov 20, 2026Latest source record: Oct 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

May 30, 2024

Primary completion

Dec 2026

Study completion Feb 2027

Sponsor

Sponsor type
Industry
First posted
Apr 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was an open-label phase I study to evaluate the safety, tolerability, PK profile and potential efficacy of SSGJ-705 as a single agent in patients with advanced malignancies.

Conditions

  • Locally Advanced, Recurrent or Metastatic Malignancies

Interventions

  • SSGJ-705Drug

    anti-PD-1 and anti-HER2 bispecific antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTsTime frame: 14 days
  2. AETime frame: up to 1 year
  3. MTD or MADTime frame: up to 1 year
  4. RP2DTime frame: up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.